medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2024, Number 2

<< Back Next >>

Rev Mex Urol 2024; 84 (2)

Pioglitazone and its relation to bladder cancer. Systematic review

Cruz BMA, Cruz BMA, Cisneros EFF, Guerrero-Ortiz FB

Language: Spanish
References: 33
Page: 1-17
PDF size: 180.58 Kb.


ABSTRACT

Description: bladder cancer is a public health problem since it is among the 10 most frequent cancers in men, it is related to multiple risk factors among which Pioglitazone stands out.
Relevance: there is controversy in the results of the different studies regarding the true relationship between Pioglitazone and bladder cancer, since some support its relationship, while in others there is no association.
Conclusions: more studies are still needed to definitively establish the true relationship since the current information is contradictory.


REFERENCES

  1. Organizacón Panamericana de la Salud.Cáncer. 2020.

  2. Centros para el Control y la Prevención deEnfermedades. Cáncer de vejiga. 2023.

  3. Centros para el Control y la Prevención deEnfermedades. Datos y estadísticas del cáncer.2023 Jun [Accessed 16th April 2024]. https://www.cdc.gov/spanish/cancer/dcpc/data/index.htm [Accessed 16th April 2024].

  4. International Agency for Research on Cancer.Cancer statistics in Mexico. 2020.

  5. Corral Cordero F, Cueva Ayala P, YépezMaldonado J, Tarupi Montenegro W. Tendenciasen incidencia y mortalidad por cáncer durantetres decadas en Quito - Ecuador. ColombiaMédica. 2018;49(1): 35–41. https://doi.org/10.25100/cm.v49i1.3785.

  6. American Cancer Society. Factores de riesgo decáncer de vejiga. American Cancer Society,. 2017.

  7. Agencia Española de, Medicamentos yProductos Sanitarios (AEMPS). Pioglitazona:resultados de la evaluación europea sobre suposible asociación con el cáncer de vejiga. AgenciaEspañola de Medicamentos y ProductosSanitarios (AEMPS). 2011.

  8. Carrillo E. Asociación Latinoamericanade Diabetes (2015). Guías ALAD sobre eldiagnóstico, control y tratamiento de la diabetesmellitus tipo 2 con medicina basada en evidencia:Asociación Latinoamericana de Diabetes. RevistaPsicología. 2015;34(1): 167–167.

  9. Kojdamanian Favetto V. Guía NICE 2022:actualización en el manejo de la diabetesmellitus tipo 2 en personas adultas. Evidencia,actualizacion en la práctica ambulatoria.2022;25(2): e007015–e007015. https://doi.org/10.51987/evidencia.v25i3.7015.

  10. Food & Drung Admistration. 2016Comunicaciones de la FDA sobre la seguridad delos medicamentos. FDA. 2019; https://www.fda.gov/drugs/drug-safety-and-availability/2016-comunicaciones-de-la-fda-sobre-la-seguridadde-los-medicamentos

  11. Nicolau Ramis J, Masmiquel Comas L. Losnuevos antidiabéticos en el punto de mira...¿razones de seguridad o caza de brujas?Endocrinol. nutr. (Ed. impr.). 2012;59(1): 1–8.

  12. Food & Drung Admistration. Una revisiónactualizada de la FDA concluye que el uso delmedicamento pioglitazona para la diabetes tipo2 puede estar vinculado a un aumento del riesgode cáncer de vejiga. FDA. 2019; https://www.fda.gov/drugs/drug-safety-and-availability/una-revision-actualizada-de-la-fda-concluyeque-el-uso-del-medicamento-pioglitazona-parala-diabetes

  13. Colmers IN, Bowker SL, Majumdar SR,Johnson JA. Use of thiazolidinediones and therisk of bladder cancer among people with type2 diabetes: a meta-analysis. Canadian MedicalAssociation Journal. 2012;184(12): E675–E683.https://doi.org/10.1503/cmaj.112102.

  14. Piccinni C, Motola D, Marchesini G, PoluzziE. Assessing the Association of PioglitazoneUse and Bladder Cancer Through Drug AdverseEvent Reporting. Diabetes Care. 2011;34(6):1369–1371. https://doi.org/10.2337/dc10-2412.

  15. Instituto Nacional del Cáncer. Causas y factoresde riesgo del cáncer de vejiga. 2022 [Accessed18th April 2024]. https://www.cancer.gov/espanol/tipos/vejiga/causas-factores-riesgo[Accessed 18th April 2024].

  16. Lewis JD, Ferrara A, Peng T, HeddersonM, Bilker WB, Quesenberry CP, et al. Riskof bladder cancer among diabetic patientstreated with pioglitazone: interim report ofa longitudinal cohort study. Diabetes Care.2011;34(4): 916–922. https://doi.org/10.2337/dc10-1068.

  17. Filipova E, Uzunova K, Kalinov K, Vekov T.Pioglitazone and the Risk of Bladder Cancer:A Meta-Analysis. Diabetes Therapy. 2017;8(4):705–726. https://doi.org/10.1007/s13300-017-0273-4.

  18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I,Hoffmann TC, Mulrow CD, et al. DeclaraciónPRISMA 2020: una guía actualizada para lapublicación de revisiones sistemáticas. RevistaEspañola de Cardiología. 2021;74(9): 790–799.https://doi.org/10.1016/j.recesp.2021.06.016.

  19. Critical Appraisal Skills Programme Español.Lista de verificación de revisión sistemática.Critical Appraisal Skills Programme Español.

  20. 2020.20. Critical Appraisal Skills Programme Español.Instrumentos para la lectura crítica. CriticalAppraisal Skills Programme Español. 2015.

  21. Davidson MB, Pan D. An updated metaanalysisof pioglitazone exposure and bladdercancer and comparison to the drug’s effecton cardiovascular disease and non-alcoholicsteatohepatitis. Diabetes Research and ClinicalPractice. 2018;135: 102–110. https://doi.org/10.1016/j.diabres.2017.11.002.

  22. Riaz A, Khan K, Afreen B, Kazmi I. BladderCancer In Patients With Type 2 Diabetes TreatedWith Pioglitazone, A Comparative Study.Journal of Ayub Medical College, Abbottabad:JAMC. 2018;30(3): 356–359.

  23. Agrawal P, Jain A, Gautam A, Nigam AK,Pursnani N, Farooqui M. A retrospective studyto assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone.Perspectives in Clinical Research. 2021;12(1):9–13. https://doi.org/10.4103/picr.picr_192_18.

  24. Adil M, Khan RA, Ghosh P, Venkata SK,Kandhare AD, Sharma M. Pioglitazone and riskof bladder cancer in type 2 diabetes mellituspatients: A systematic literature review andmeta-analysis of observational studies usingreal-world data. Clinical Epidemiology andGlobal Health. 2018;6(2): 61–68. https://doi.org/10.1016/j.cegh.2017.08.002.

  25. Garry EM, Buse JB, Lund JL, Pate V, StürmerT. Comparative safety of pioglitazone versusclinically meaningful treatment alternativesconcerning the risk of bladder cancer in olderUS adults with type 2 diabetes. Diabetes, Obesity& Metabolism. 2018;20(1): 129–140. https://doi.org/10.1111/dom.13049.

  26. Yan H, Xie H, Ying Y, Li J, Wang X, Xu X, etal. Pioglitazone use in patients with diabetesand risk of bladder cancer: a systematic reviewand meta-analysis. Cancer Management andResearch. 2018;10: 1627–1638. https://doi.org/10.2147/cmar.s164840.

  27. Malhotra B, Hiteshi P, Khalkho P, Malik R,Bhadada SK, Bhansali A, et al. Bladder cancerwith pioglitazone: A case-control study. Diabetes& Metabolic Syndrome. 2022;16(11): 102637.https://doi.org/10.1016/j.dsx.2022.102637.

  28. Ramezannezhad P, Khosravifarsani M. Theassociation between pioglitazone consumptionand incidence of bladder cancer in type IIdiabetic patients: a systematic review andmeta-analysis of observational studies. Journalof Nephropathology. 2023;12(2). http://dx.doi.org/10.34172/jnp.2023.21443

  29. Bhushan S, Ray RS, Prakash J, Singh GN. GlobalVersus Indian Perspective of PioglitazoneinducedAdverse Drug Reactions IncludingBladder Cancer: A Comparative RetrospectivePharmacovigilance Analysis. ClinicalTherapeutics. 2019;41(11): 2252–2262. https://doi.org/10.1016/j.clinthera.2019.08.018.

  30. Tang H, Shi W, Fu S, Wang T, Zhai S, SongY, et al. Pioglitazone and bladder cancer risk:a systematic review and meta-analysis. CancerMedicine. 2018;7(4): 1070–1080. https://doi.org/10.1002/cam4.1354.

  31. Sinha B, Ghosal S. Assessing the need forpioglitazone in the treatment of patients withtype 2 diabetes: a meta-analysis of its risksand benefits from prospective trials. ScientificReports. 2020;10(1): 15781. https://doi.org/10.1038/s41598-020-72967-8.

  32. Li YR, Liu CH, Sun WC, Fan PY, Liu FH, ChenTH, et al. The Risk of Bladder Cancer in Type2 Diabetes Mellitus with Combination Therapyof SGLT-2 Inhibitors and Pioglitazone. Journal ofPersonalized Medicine. 2021;11(9): 828. https://doi.org/10.3390/jpm11090828.

  33. Ripamonti E, Azoulay L, Abrahamowicz M,Platt RW, Suissa S. A systematic review ofobservational studies of the association betweenpioglitazone use and bladder cancer. DiabeticMedicine: A Journal of the British DiabeticAssociation. 2019;36(1): 22–35. https://doi.org/10.1111/dme.13854.




2020     |     www.medigraphic.com